Barclays’s Passage Bio PASG Stock Holding History

Barclays’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03K	Hold	212	–	–	﹤0.01%	4929
2026 Q1	$1.66K	Hold	212	–	–	﹤0.01%	4868
2025 Q4	$2.5K	Hold	212	–	–	﹤0.01%	5032
2025 Q3	$1.7K	Buy	212 +1	+0.5%	+$7	﹤0.01%	5155
2025 Q2	$1.69K	Hold	211	–	–	﹤0.01%	5046
2025 Q1	$1.49K	Sell	211 -447	-68%	-$4.83K	﹤0.01%	5018
2024 Q4	$7.46K	Hold	658	–	–	﹤0.01%	5023
2024 Q3	$9.21K	Hold	658	–	–	﹤0.01%	4982
2024 Q2	$10.4K	Hold	658	–	–	﹤0.01%	4514
2024 Q1	$17.8K	Hold	658	–	–	﹤0.01%	4766
2023 Q4	$13.3K	Hold	658	–	–	﹤0.01%	4949
2023 Q3	$8.65K	Hold	658	–	–	﹤0.01%	4324
2023 Q2	$12.4K	Hold	658	–	–	﹤0.01%	4204
2023 Q1	$12.6K	Hold	658	–	–	﹤0.01%	4718
2022 Q4	$18.2K	Hold	658	–	–	﹤0.01%	4825
2022 Q3	$16K	Sell	658 -20	-3%	-$788	﹤0.01%	4142
2022 Q2	$32K	Sell	678 -319	-32%	-$14.9K	﹤0.01%	4220
2022 Q1	$62K	Buy	+997	New	+$82.2K	﹤0.01%	4022

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Barclays's PASG Position: Q2 2026 in Review

Barclays held its Passage Bio (PASG) position steady in Q2 2026 at 212 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4929.

Barclays first reported a position in PASG in Q1 2022 and has held it in 18 quarters since. The position peaked at $62K in Q1 2022. 29 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

Barclays held 212 shares of Passage Bio worth $1.03K as of Q2 2026.
Barclays left its Passage Bio share count unchanged in Q2 2026.
Passage Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4929 holding.
Barclays first reported a position in Passage Bio in Q1 2022 and has held it in 18 quarters since.
Barclays's Passage Bio position peaked at $62K in Q1 2022.
29 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.